Drug Profile

Sutacimig - Hemab Therapeutics

Alternative Names: HMB-001

Latest Information Update: 13 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hemab
Class Antihaemorrhagics; Bispecific antibodies; Recombinant proteins
Mechanism of Action Factor VIIa modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Thrombasthenia
New Molecular Entity Yes

Highest Development Phases

Phase I/II Thrombasthenia
Preclinical Factor VII deficiency

Most Recent Events

05 Mar 2026 Sutacimig - Hemab Therapeutics receives Breakthrough Therapy status for Thrombasthenia in USA
08 Dec 2025 Efficacy, adverse events and immunogenicity data from a phase I/II trial in Thrombasthenia released by Hemab
08 Dec 2025 Hemab plans a pivotal phase III registrational trial in Thrombasthenia in 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com